Soleno Therapeutics to be acquired by Neurocrine Biosciences

 

 for $53 per share in cash, valuing deal at about $2.9 billion

• Transaction structured as a tender offer followed by a subsequent merger, as approved by both companies’ boards.

https://finviz.com/quote.ashx?t=SLNO&p=d